← Leaderboards
Brenda S Jones
University Of Southern California
$382,634
Attributed
$382,634
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$382,634 · 2
By mechanism
M01$382,634 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Heinz Josef Lenz$20,123,312
- William J Jusko$16,823,605
- Andrea A. Kovacs$11,647,115
- Fred R Sattler$24,195,984
- Donald B Kohn$24,055,774
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisAntitubercular AgentsClinical ResearchHiv InfectionsHuman SubjectHuman Therapy EvaluationOpportunistic InfectionsPharmacokineticsIsoniazidClinical TrialsDrug Screening /EvaluationMicroorganism Disease ChemotherapyRifamycinsAids Therapy
Grant awards (10)
RIFAPENTINE CLINICAL TRIAL--RISK FACTORS FOR RELAPSE AMONG HIV+ PTS$0
M01 · FY2002 · RR
PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PERSONS$0
M01 · FY2002 · RR
PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PERSONS$155,764
M01 · FY2001 · RR
RIFAPENTINE CLINICAL TRIAL--RISK FACTORS FOR RELAPSE AMONG HIV+ PTS$155,764
M01 · FY2001 · RR
PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PERSONS$0
M01 · FY2001 · RR
RIFAPENTINE CLINICAL TRIAL--RISK FACTORS FOR RELAPSE AMONG HIV+ PTS$0
M01 · FY2001 · RR
RIFAPENTINE CLINICAL TRIAL--RISK FACTORS FOR RELAPSE AMONG HIV+ PTS$35,553
M01 · FY2000 · RR
PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PERSONS$35,553
M01 · FY2000 · RR
PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PERSONS$0
M01 · FY2000 · RR
RIFAPENTINE CLINICAL TRIAL--RISK FACTORS FOR RELAPSE AMONG HIV+ PTS$0
M01 · FY2000 · RR